Personalized Therapy in Non-small Cell Lung Cancer (PTINCLC)
Lung Cancer, Carboplatin Adverse Reaction
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring lung cancer, gemcitabine, carboplatin, pemetrexed
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed non-small cell lung cancer
- age from 18 years to 75 years
- ECOG Performance Status no more than 2
- at least one appraisable lung focus of diameter≥ 10 mm by lung CT
- Haemoglobin ≥10.0 g/dl, Absolute neutrophil count ≥(ANC) 1.5 x 109/L, platelets ≥100 x 109/L
- Total bilirubin ≤1.5 x upper limit of normal (ULN)
- ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases
- Creatinine clearance ≥60ml/min (calculated according to Cockcroft-gault formula)
- Informed consent should be obtained before treatment.
Exclusion Criteria:
- Mixed non-adenocarcinoma cell lung cancer histology
- Previous treatment for Systemic chemotherapy or local radiotherapy
- Be allergic to chemotherapy drugs
- second active primary malignancy or serious concomitant medical disease
- difficulties with adequate follow-up
Sites / Locations
- The first affiliated hospital of Guangzhou MC
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
A.individual therapy
B. non-individualized therapy
Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.